Concepedia

Michael Gillen

MG

32

Publications

715

Citations

18

H-Index

2001

Active since

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

AstraZeneca (Sweden)

IQVIA (United Kingdom)

AstraZeneca (Japan)

Michael Gillen is an author at AstraZeneca (United States) specializing in pharmacotherapy, medicine, and pharmacology.

ORCID

Top concepts

Publications per year

2001–2020

32

Publications

32

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval

Michael Gillen, Barry Miller, Philip Chaikin et al. · British Journal of Clinical Pharmacology · 2001 · 45 citations · Full text

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies

Paul Martin, Michael Gillen, James M. Ritter et al. · Drugs in R&D · 2016 · 42 citations · Full text

Co‐administration of ketoconazole with H<sub>1</sub>‐antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects

Philip Chaikin, Michael Gillen, Marek Malík et al. · British Journal of Clinical Pharmacology · 2005 · 41 citations · Full text

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects

Zancong Shen, Michael Gillen, Jeffrey N. Miner et al. · Drug Design Development and Therapy · 2017 · 39 citations · Full text

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

R. Fleischmann, Peter Winkle, Jeffrey N. Miner et al. · RMD Open · 2018 · 39 citations · Full text

Rows per page

1–5 of 32